Elite Pharma Q3 revenue up 68% to $15.5M; operating profit up 80% to $3.5M

ELITE PHARMACEUTICALS INC /NV/

2024-Q3 EPS reported $0.02 revenue$38,676,061

Revenue $15.5M for Q3 FY2024 ended Dec 31, 2023, +68% YoY from $9.2M.
Operating profit $3.5M, +80% YoY from $1.9M.
Growth attributable to sales of Elite Laboratories label products launched during FY2024.
Company to hold conference call Feb 15, 2024 at 11:30 AM EST.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ELITE PHARMACEUTICALS INC /NV/ reported third quarter of fiscal year 2024 ended December 31, 2023 results: revenue $15.5 million.

Period: third quarter of fiscal year 2024 ended December 31, 2023
Revenue: $15.5 million
Result: reported results

Exact text from the filing

Consolidated revenues for the three-month period ended December 31, 2023, were $15.5 million, an increase of $6.3 million or 68% as compared to the comparable period of the prior fiscal year.

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

ELITE PHARMACEUTICALS INC /NV/ filing history →

Source: SEC EDGAR

accession 0001493152-24-006722

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.